Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation

Anthony M. Abang, Marc H. Takemoto, Trinh Pham, Romeo A. Mandanas, Vivek Roy, George B. Selby, Thomas H. Carter

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This randomized, controlled, double-blind pilot study assessed the efficacy and safety of oral versus i.v. granisetron, both in combination with non-5-HT3 antiemetics, in preventing emesis caused by high-dose chemotherapy. Fifty-one patients who underwent peripheral blood progenitor cell transplantation (PBPCT) or bone marrow transplantation (BMT) were evaluated. Efficacy was assessed by the number of emetic episodes during the worst 24 h period. A complete response (CR) was defined as no vomiting, partial response (PR) as less than three emetic episodes and failure as three or more emetic episodes. Patients who received oral granisetron experienced significantly (p < 0.0008) fewer emetic episodes than those who received i.v. granisetron; however, the number of emetic episodes over the worst 24 h was similar between the oral and i.v. granisetron groups (13 and 15, respectively), as were the overall response rates (CR + PR, 54.5 and 41.4%, respectively). Both dosage forms were well tolerated. Based on these findings, further comparative studies of oral granisetron are warranted in patients undergoing PBPCT or BMT. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)137-142
Number of pages6
JournalAnti-Cancer Drugs
Volume11
Issue number2
DOIs
StatePublished - Apr 19 2000
Externally publishedYes

Fingerprint

Granisetron
Emetics
Bone Marrow Transplantation
Blood Cells
Stem Cells
Safety
Cell Transplantation
Vomiting
Antiemetics
Dosage Forms
Double-Blind Method
Drug Therapy

Keywords

  • Bone marrow transplantation
  • Emesis
  • Granisetron
  • High-dose chemotherapy
  • Peripheral blood progenitor cell transplantation

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation. / Abang, Anthony M.; Takemoto, Marc H.; Pham, Trinh; Mandanas, Romeo A.; Roy, Vivek; Selby, George B.; Carter, Thomas H.

In: Anti-Cancer Drugs, Vol. 11, No. 2, 19.04.2000, p. 137-142.

Research output: Contribution to journalArticle

Abang, Anthony M. ; Takemoto, Marc H. ; Pham, Trinh ; Mandanas, Romeo A. ; Roy, Vivek ; Selby, George B. ; Carter, Thomas H. / Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation. In: Anti-Cancer Drugs. 2000 ; Vol. 11, No. 2. pp. 137-142.
@article{024572a6a94b4758967447c055d5efd1,
title = "Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation",
abstract = "This randomized, controlled, double-blind pilot study assessed the efficacy and safety of oral versus i.v. granisetron, both in combination with non-5-HT3 antiemetics, in preventing emesis caused by high-dose chemotherapy. Fifty-one patients who underwent peripheral blood progenitor cell transplantation (PBPCT) or bone marrow transplantation (BMT) were evaluated. Efficacy was assessed by the number of emetic episodes during the worst 24 h period. A complete response (CR) was defined as no vomiting, partial response (PR) as less than three emetic episodes and failure as three or more emetic episodes. Patients who received oral granisetron experienced significantly (p < 0.0008) fewer emetic episodes than those who received i.v. granisetron; however, the number of emetic episodes over the worst 24 h was similar between the oral and i.v. granisetron groups (13 and 15, respectively), as were the overall response rates (CR + PR, 54.5 and 41.4{\%}, respectively). Both dosage forms were well tolerated. Based on these findings, further comparative studies of oral granisetron are warranted in patients undergoing PBPCT or BMT. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Bone marrow transplantation, Emesis, Granisetron, High-dose chemotherapy, Peripheral blood progenitor cell transplantation",
author = "Abang, {Anthony M.} and Takemoto, {Marc H.} and Trinh Pham and Mandanas, {Romeo A.} and Vivek Roy and Selby, {George B.} and Carter, {Thomas H.}",
year = "2000",
month = "4",
day = "19",
doi = "10.1097/00001813-200002000-00011",
language = "English (US)",
volume = "11",
pages = "137--142",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Efficacy and safety of oral granisetron versus i.v. granisetron in patients undergoing peripheral blood progenitor cell and bone marrow transplantation

AU - Abang, Anthony M.

AU - Takemoto, Marc H.

AU - Pham, Trinh

AU - Mandanas, Romeo A.

AU - Roy, Vivek

AU - Selby, George B.

AU - Carter, Thomas H.

PY - 2000/4/19

Y1 - 2000/4/19

N2 - This randomized, controlled, double-blind pilot study assessed the efficacy and safety of oral versus i.v. granisetron, both in combination with non-5-HT3 antiemetics, in preventing emesis caused by high-dose chemotherapy. Fifty-one patients who underwent peripheral blood progenitor cell transplantation (PBPCT) or bone marrow transplantation (BMT) were evaluated. Efficacy was assessed by the number of emetic episodes during the worst 24 h period. A complete response (CR) was defined as no vomiting, partial response (PR) as less than three emetic episodes and failure as three or more emetic episodes. Patients who received oral granisetron experienced significantly (p < 0.0008) fewer emetic episodes than those who received i.v. granisetron; however, the number of emetic episodes over the worst 24 h was similar between the oral and i.v. granisetron groups (13 and 15, respectively), as were the overall response rates (CR + PR, 54.5 and 41.4%, respectively). Both dosage forms were well tolerated. Based on these findings, further comparative studies of oral granisetron are warranted in patients undergoing PBPCT or BMT. (C) 2000 Lippincott Williams and Wilkins.

AB - This randomized, controlled, double-blind pilot study assessed the efficacy and safety of oral versus i.v. granisetron, both in combination with non-5-HT3 antiemetics, in preventing emesis caused by high-dose chemotherapy. Fifty-one patients who underwent peripheral blood progenitor cell transplantation (PBPCT) or bone marrow transplantation (BMT) were evaluated. Efficacy was assessed by the number of emetic episodes during the worst 24 h period. A complete response (CR) was defined as no vomiting, partial response (PR) as less than three emetic episodes and failure as three or more emetic episodes. Patients who received oral granisetron experienced significantly (p < 0.0008) fewer emetic episodes than those who received i.v. granisetron; however, the number of emetic episodes over the worst 24 h was similar between the oral and i.v. granisetron groups (13 and 15, respectively), as were the overall response rates (CR + PR, 54.5 and 41.4%, respectively). Both dosage forms were well tolerated. Based on these findings, further comparative studies of oral granisetron are warranted in patients undergoing PBPCT or BMT. (C) 2000 Lippincott Williams and Wilkins.

KW - Bone marrow transplantation

KW - Emesis

KW - Granisetron

KW - High-dose chemotherapy

KW - Peripheral blood progenitor cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=0034067385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034067385&partnerID=8YFLogxK

U2 - 10.1097/00001813-200002000-00011

DO - 10.1097/00001813-200002000-00011

M3 - Article

VL - 11

SP - 137

EP - 142

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 2

ER -